Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179980 | 0.79 | HTR6 (0.63) | HTR6LMNAMAPK1MEN1KMT2A | |
| SCHEMBL9958221 | 0.78 | HTR6 (0.62) | HTR6LMNAMAPK1MEN1KMT2A | |
| SCHEMBL8501386 | 0.77 | HTR6 (0.51) | HTR6LMNAMAPK1MEN1KMT2A | |
| SCHEMBL8378573 | 0.76 | CA12 (0.37) | HTR6MEN1KMT2AALDH1A1KEAP1 | |
| SCHEMBL2474943 | 0.74 | LMNA (0.56) | HTR6LMNAMAPK1MEN1KMT2A | |
| SCHEMBL29586241 | 0.74 | LMNA (0.59) | HTR6LMNAMAPK1MEN1KMT2A | |
| SCHEMBL3824499 | 0.74 | LMNA (0.59) | HTR6LMNAMAPK1MEN1KMT2A | |
| SCHEMBL11302211 | 0.73 | ALDH1A1 (0.56) | HTR6LMNAMAPK1MEN1KMT2A | |
| SCHEMBL941645 | 0.72 | LMNA (0.57) | HTR6LMNAMAPK1MEN1KMT2A | |
| SCHEMBL6938252 | 0.72 | ALDH1A1 (0.61) | LMNAMAPK1MEN1KMT2AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580379-B2 | Xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580379-B2 | Xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2017-02-28 | — | — | US | disclosed |
| WO-2015191635-A2 | XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | BAYLOR COLLEGE OF MEDICINE (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20150353471-A1 | XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | BAYLOR COLLEGE OF MEDICINE | 2015-12-10 | — | — | US | disclosed |
| US-20150353471-A1 | XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | BAYLOR COLLEGE OF MEDICINE | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353471-A1 | XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | XDH, PNPO, AOX1 | HTR6 1940/4885LMNA 1909/4885MAPK1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.